1,133 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Acquired by Fiduciary Trust Co.

Fiduciary Trust Co. bought a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 1,133 shares of the pharmaceutical company’s stock, valued at approximately $209,000.

Several other large investors have also recently modified their holdings of VRTX. FMR LLC boosted its position in Vertex Pharmaceuticals by 13.3% during the fourth quarter. FMR LLC now owns 20,483,109 shares of the pharmaceutical company’s stock worth $3,394,256,000 after purchasing an additional 2,411,631 shares during the period. Vanguard Group Inc boosted its position in Vertex Pharmaceuticals by 1.2% during the third quarter. Vanguard Group Inc now owns 18,775,252 shares of the pharmaceutical company’s stock worth $3,618,743,000 after purchasing an additional 213,550 shares during the period. Jennison Associates LLC boosted its position in Vertex Pharmaceuticals by 11.9% during the fourth quarter. Jennison Associates LLC now owns 6,941,621 shares of the pharmaceutical company’s stock worth $1,150,296,000 after purchasing an additional 739,128 shares during the period. Oregon Public Employees Retirement Fund boosted its position in Vertex Pharmaceuticals by 16,530.8% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 4,610,881 shares of the pharmaceutical company’s stock worth $28,000 after purchasing an additional 4,583,156 shares during the period. Finally, Geode Capital Management LLC boosted its position in Vertex Pharmaceuticals by 7.3% during the fourth quarter. Geode Capital Management LLC now owns 3,059,306 shares of the pharmaceutical company’s stock worth $505,995,000 after purchasing an additional 207,934 shares during the period. Institutional investors own 95.08% of the company’s stock.

A number of equities analysts have recently commented on VRTX shares. ValuEngine lowered shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 18th. Citigroup restated a “buy” rating and issued a $205.00 price objective on shares of Vertex Pharmaceuticals in a research report on Thursday, May 23rd. Goldman Sachs Group restated a “buy” rating and issued a $220.00 price objective on shares of Vertex Pharmaceuticals in a research report on Thursday, May 23rd. BidaskClub upgraded shares of Vertex Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, May 24th. Finally, Cowen reiterated a “buy” rating and set a $220.00 target price on shares of Vertex Pharmaceuticals in a research report on Tuesday, April 30th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and seventeen have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $204.36.

In related news, EVP Stuart A. Arbuckle sold 5,624 shares of Vertex Pharmaceuticals stock in a transaction on Monday, April 15th. The shares were sold at an average price of $181.75, for a total value of $1,022,162.00. Following the transaction, the executive vice president now directly owns 36,272 shares of the company’s stock, valued at $6,592,436. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Paul M. Silva sold 161 shares of Vertex Pharmaceuticals stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $165.41, for a total transaction of $26,631.01. Following the completion of the sale, the senior vice president now owns 17,759 shares in the company, valued at approximately $2,937,516.19. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 165,399 shares of company stock worth $28,980,388. 0.70% of the stock is owned by insiders.

Shares of VRTX stock traded up $1.33 during trading hours on Friday, hitting $170.22. 781,247 shares of the company’s stock were exchanged, compared to its average volume of 1,359,626. The company has a market capitalization of $43.70 billion, a PE ratio of 60.15, a price-to-earnings-growth ratio of 2.48 and a beta of 1.48. Vertex Pharmaceuticals Incorporated has a 12-month low of $145.37 and a 12-month high of $195.81. The company has a debt-to-equity ratio of 0.13, a quick ratio of 3.66 and a current ratio of 3.78.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Tuesday, April 30th. The pharmaceutical company reported $1.14 EPS for the quarter, topping the consensus estimate of $0.65 by $0.49. Vertex Pharmaceuticals had a net margin of 66.01% and a return on equity of 22.63%. The firm had revenue of $857.00 million for the quarter, compared to the consensus estimate of $853.00 million. During the same period last year, the firm posted $0.76 earnings per share. The business’s revenue was up 34.3% compared to the same quarter last year. On average, research analysts predict that Vertex Pharmaceuticals Incorporated will post 3.06 EPS for the current year.

TRADEMARK VIOLATION WARNING: “1,133 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Acquired by Fiduciary Trust Co.” was first published by Sundance Herald and is owned by of Sundance Herald. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at https://sundanceherald.com/2019/06/14/fiduciary-trust-co-purchases-new-position-in-vertex-pharmaceuticals-incorporated-vrtx.html.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene.

Recommended Story: Why are gap-down stocks important?

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply